The activation of mitogen-activated protein kinases (MAPKs) is critically involved in inflammatory events through mediation of the production of various inflammatory cytokines. The Tpl2 (tumor progression locus 2)-MEK (MAPK/ERK kinase)-ERK (extracellular signal-regulated kinase) signaling pathway plays an essential role in the production of tumor necrosis factor a (TNFa) in macrophages stimulated with lipopolysaccharide (LPS). Here, we studied the molecular mechanisms of Tpl2-mediated TNFa production using a potent Tpl2 kinase inhibitor, 1,7-naphtyridine-3-carbonitrile, and LPS-stimulated RAW264.7 cells. This inhibitor was effective in suppressing the in vitro Tpl2 kinase activity, and caused a significant reduction in TNFa production via specific suppression of the phosphorylation of MEK and ERK but not that of p38 and c-Jun N-terminal kinase (JNK). A p38 inhibitor, SB203580, also inhibited the TNFa production dose-dependently. Although the TNFa mRNA level was not altered by either inhibitor, the Tpl2 inhibitor increased the nuclear TNFa mRNA level, while decreasing that in the cytoplasm. Tip-associated protein (TAP), a key molecule in the nucleocytoplasmic transport of TNFa mRNA, was up-regulated by LPS, but this increase was impaired by the Tpl2 inhibitor. In all cases, SB203580 was without effect in the presence of LPS. These results suggest that the LPS-induced TNFa production via the Tpl2-MEK-ERK signaling pathway is regulated by changing the TAP level at the nucleocytoplasmic transport level. These results improve understanding of TNFa regulatory mechanisms and might provide a new therapeutic strategy against inflammatory diseases.
Tumor necrosis factor a (TNFa) is one of the major proinflammatory cytokines in the pathogenesis of inflammatory disorders such as rheumatoid arthritis (RA). 1, 2) In fact, biological therapeutics including soluble TNF receptor and monoclonal antibodies for the neutralization of TNFa, such as Eternercept (soluble TNFR-Fc), infliximab, and adalimumab (anti-TNFa antibodies), have been developed and are now powerful therapeutic options. Therefore, revealing the signaling pathways of TNFa production is very important for the understanding of its pathological basis and to facilitate drug discoveries.
TNFa is induced by a variety of inflammatory cytokines and many external stimuli, including lipopolysaccharide (LPS), mainly in macrophages. TNFa production by LPS is controlled at both transcriptional and post-transcriptional levels. 3) At the transcriptional level, many transcription factors, including nuclear factor kappa B (NF-kB), activating transcription factor-2 (ATF-2), c-Jun, and nuclear factor of activated T-cells (NFAT), are involved in TNFa mRNA expression. [4] [5] [6] Post-transcriptional regulation consists of three phases: mRNA stability, mRNA nucleocytoplasmic transport, and translation. The post-transcriptional regulation of TNFa expression is mediated through an AU-rich element (ARE) in the 3Ј-untranslated region of the mRNA. The ARE-dependent stabilization of TNFa mRNA is regulated by c-Jun N-terminal kinase (JNK) and p38 MAPK pathways activated by LPS. 7) Moreover, ARE regions are involved in mRNA nucleocytoplasmic transport.
8) The transport of mRNA from the nucleus to the cytoplasm is an essential step in eukaryotic gene expression. Various proteins including UAP56, REF (RNA and export factor-binding proteins)/ALY, TAP (tip-associated protein)/NXF1 (nuclear export factor 1), and NXT1 (nuclear transport factor 2 (NTF2)-related export protein 1) are involved in mRNA export. The major exporter of mRNAs is the TAP-NXT1 heterodimer. 9, 10) The TAP-NXT1 complex interacts with AU-rich element-binding proteins to control the extracellular signal-regulated kinase 1 (ERK1)-regulated TNFa mRNA export. 8) However, these transcriptional and/or post-transcriptional regulatory mechanisms of TNFa are not fully understood.
Tpl2 (tumor progression locus 2)/Cot (cancer Osaka thyroid) is a serine/threonine protein kinase, and is a member of the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family known to regulate the activation of MAP kinase signaling pathways. [11] [12] [13] Tpl2 plays an essential role in the production of TNFa in macrophages stimulated by LPS. Tpl2-deficient mice produce low levels of TNFa when they are inoculated with LPS and are resistant to LPS/Dgalactosamine-induced endotoxin shock. 12) Moreover, Tpl2 ablation inhibits the nucleocytoplasmic transport of TNFa mRNA.
12) Here, we used a selective and potent inhibitor of Tpl2 14) to better understand the Tpl2-MAPK/ERK kinase (MEK)-ERK signaling mechanisms focusing on the nucleocytoplasmic transport of TNFa mRNA. 6 cells were spread in a 10-cm dish and maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, NY, U.S.A.), supplemented with 10% heatinactivated fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 mg/ml) under 95% air and 5% CO 2 at 37°C.
MATERIALS AND METHODS

Materials
Western Blotting The treated RAW264.7 cells were washed with cold phosphate buffered saline (PBS) and disrupted by adding 100 ml of a lysis buffer consisting of 50 mM Tris-acetate (pH 7.5), 0.1 M NaCl, 1 mM each of ethylenediaminetetraacetic acid (EDTA), ethylene glycol bis(2-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA), sodium orthovanadate, sodium fluoride, dithiothreitol (DTT), and b-glycerophosphate, and 2.5 mM sodium pyrophosphate, 0.5 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, and a proteinase inhibitor mixture (1 tablet/10 ml; Roche Diagnostics, NJ, U.S.A.). In some of the experiments, the treated cells were fractionated into nuclear and cytoplasmic fractions using an NE-PER TM kit (PIERCE, IL, U.S.A.). Each cell lysate was subjected to Western blotting. The blotted membrane was incubated in a blocking solution (5% nonfat dried milk in tris buffered saline (TBS) containing 0.1% Tween 20) followed by treatment with the primary antibodies and with the secondary horseradish-peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G (IgG) antibodies. The membrane was incubated with a chemical luminescence detection solution and exposed to X-ray film.
Tpl2 Kinase Activity Assay The Tpl2 kinase activity was estimated by measuring the phosphorylated level of MEK1 by Western blotting. Five hundred micrograms of cell lysates from 6-well plates were incubated with 2 mg of antiTpl2 antibody at 4°C for 4 h and with 20 ml of protein A/G agarose beads (Santa Cruz Biotechnology) for another 1 h. After centrifugation, the precipitate was reacted with 1 mg of the substrate glutathione S-transferase (GST)-MEK1 (Millipore, MA, U.S.A.) in a 40 ml solution consisting of 50 mM Tris-acetate (pH 7.5), 0.1 mM EGTA, 0.1 mM sodium orthovanadate, 10 mM magnesium acetate, 200 mM ATP, 0.1% 2-mercaptoethanol, and 0.03% Brij 35 at 30°C for 30 min. The reactant was subjected to Western blotting using an antiphospho-MEK antibody.
Enzyme-Linked Immunosorbent Assay (ELISA) for TNFa Production RAW264.7 cells were preincubated with Tpl2 inhibitor or SB203580 at 0.1, 1.0, and 10 mM for 30 min and then stimulated with LPS (20 ng/ml) for 4 h. The culture medium was collected, and TNFa therein was determined by the ELISA method (Duoset mouse TNFa ELISA kit; R&D Systems, MN, U.S.A.).
Cell Viability Check The cell viability after addition of the inhibitor was monitored by measuring lactate dehydrogenase activity in the medium using an LDH-Cytotoxic test kit (Wako, Osaka, Japan).
Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) In some of the experiments, the treated cells were fractionated into nuclear and cytoplasmic fractions using an NE-PER TM kit. Total RNA was extracted from the treated cells or fractionated samples with an RNeasy TM kit (Qiagen, MD, U.S.A.). Five hundred nanograms of total RNA was reverse-transcribed to cDNA using a PrimeScript RT TM reagent kit (Takara Bio, Shiga, Japan). qRT-PCR was carried out by a combination of an SYBR premix EX Taq II TM (Takara Bio) with an Mx3000P TM real-time PCR system (Stratagene, CA, U.S.A.). The PCR primers were: TNFa sense primer, 5Ј-AGC CCC CAG TCT GTA TCC TT-3Ј; TNFa antisense primer, 5Ј-GAG GCA ACC TGA CCA CTC TC-3Ј; TAP sense primer, 5Ј-AGA GGT GGT TCT GGT GTA CAG TCT T-3Ј; TAP antisense primer, 5Ј-GAG CTC TGT CTC TCC GTA CAG TAA T-3Ј; NXT1 sense primer, 5Ј-GAA GAG GAG AAC AGG AGA GAA ACT C-3Ј; NXT1 antisense primer, 5Ј-CCG CTT ATC CAT AGT CGT GTA ATA G-3Ј; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense primer, 5Ј-TGA AGC AGG CAT CTG AGG G-3Ј; GAPDH antisense primer, 5Ј-CGA AGG TGG AAG AGT GGG AG-3Ј. The PCR condition was as follows: 95°C for 10 s for initial denaturation, and 40 cycles of denaturation at 95°C for 5 s followed by annealing/elongation at 55°C for 35 s. GAPDH was used as an internal control. NF-kB Activity Measurements The nuclear extract was prepared from the cells as described above, and the DNAbinding activity of NF-kB was determined by the ELISA method in accordance with the manufacturer's instructions in a TransAM TM NF-kB p65 kit (ACTIVE MOTIF, CA, U.S.A.).
RESULTS AND DISCUSSION
Tpl2 Inhibitor Suppresses Tpl2-MEK-ERK Activation
Induced by LPS To gain more insight into the regulatory mechanisms of TNFa production, we utilized a Tpl2 inhibitor, possessing an inhibitory effect on TNFa production, with LPS-stimulated human monocytes. 15) This series of compounds are reported to be quite specific for Tpl2 with an IC 50 of 12-50 nM. The inhibitory potency is at least 2000-to 10000-fold higher than those for other protein kinases such as Raf-1, MEK, p38, and CaMKII. 15) We first confirmed whether this inhibitor suppresses the kinase activity of Tpl2 isolated from LPS-stimulated RAW264.7 cells. Tpl2 kinase activity assessed by MEK phosphorylation was increased by the LPS treatment, and the Tpl2 inhibitor suppressed the phosphorylation (Fig. 1A) . According to Caivano's report, LPS stimulation causes the activation of the MAPK cascade through the Tpl2-MEK-ERK pathway, whereas phorbol 12-myristate 13-acetate (PMA) stimulation activates the MAPK cascade through Raf-1-MEK-ERK activation. 16) We evaluated the functional specificity of the Tpl2 inhibitor by monitoring the signaling pathway of LPS or PMA stimulation. As expected, Tpl2 inhibitor decreased the activation of the MEK and ERK but not JNK and p38 MAP kinases in the cells stimulated with LPS (Fig. 1B) . When RAW264.7 cells were stimulated with PMA, the phosphorylation states of MEK and ERK were not affected by the compound. These results show that the Tpl2 inhibitor suppresses the Tpl2-MEK-ERK signaling pathway specifically.
Tpl2 Inhibitor Suppresses the Nucleocytoplasmic
Transport of TNFa mRNA Induced by LPS We next investigated the inhibitory activity of the compound on LPSinduced TNFa production at the molecular level. This compound inhibited the production of TNFa concentrationdependently and yielded 60% inhibition at 10 mM, where the cell viability was not affected as assessed by lactate dehydrogenase release (data not shown) ( Fig. 2A) . To investigate an- other MAPK cascade of TNFa production, we used a potent p38 inhibitor, SB203580. It inhibited the production of TNFa in a fashion similar to that of Tpl2 (Fig. 2A) . We next examined the involvement of Tpl2 in transcriptional regulation (Fig. 2B) . Neither Tpl2 inhibitor nor SB203580 suppressed the TNFa mRNA expression during LPS stimulation. In addition, LPS-induced activation of NF-kB, the key molecule in TNFa gene transcription, was not affected by the Tpl2 inhibitor or SB203580 (data not shown). Therefore, the Tpl2 or p38 pathway does not influence TNFa gene transcriptional control including TNFa mRNA stability. These results are consistent with those of a study of mice that lack p38 substrate MAPKAPK-2 and Kontoyiannis' report that indicates a role for the p38 pathway in the regulation of TNFa expression at the translational level. 17, 18) It was reported that the nucleocytoplasmic transport of TNFa mRNA requires the Tpl2-MEK-ERK signaling pathway following a study of Tpl2-gene-deficient mice. 12) We confirmed these results using the Tpl2 inhibitor. As shown in Fig. 2C , Tpl2 inhibitor tended to increase the nuclear TNFa mRNA level, whereas significantly reduced the cytoplasmic TNFa mRNA level. This result is consistent with the results of the Tpl2-deficient-mice study. On the other hand, SB203580 had a negligible effect on the cytoplasmic TNFa mRNA level. These results suggested that LPS-induced nucleocytoplasmic transport of TNFa mRNA might be regulated by the Tpl2-MEK-ERK signaling pathway but not the p38 pathway.
Tpl2 Inhibitor Inhibits an Increment of TAP Induced by LPS The nucleocytoplasmic transport of TNFa mRNA requires the TNFa AU-rich elements located in the 3ЈUTR of TNFa mRNA, and is regulated by the protein complex of TAP and NXT1. 8) We next investigated whether Tpl2 regulates the expression of TAP and/or NXT1 in the LPS-stimulated cells. At the mRNA level, the expressions of TAP and NXT1 were not affected by LPS stimulation (Fig. 3A) . At the protein level, however, the expression of TAP in the nuclear fraction was increased by LPS stimulation and reached its peak within 1 h after stimulation (Fig. 3B) . The TAP mRNA level was still unchanged in this time-course (not shown). This inconsistent finding may be explained as follows: 1) the availability of the TAP mRNA as translation template is elevated by a conformational change itself; 2) the TAP protein synthesis is specifically enhanced by the activation of ribosome (so-called translational control), and so on. TAP and lamin B, the latter being a nuclear localization marker, were 1236 Vol. 33, No. 7 seen at trace levels in the cytosolic fraction. Although it is unknown whether these trace amounts are due to the contamination from the nucleus during preparation, neither level was substantially affected by the LPS stimulation. Glyceraldehyde-3-phosphate dehydrogenase is known to occur in the nucleus at an appreciable amount. 19 ) Finally, we addressed whether the increase of TAP in the nucleus is influenced by the Tpl2 inhibitor or SB203580. Figure 3C clearly shows that the TAP level from the Tpl2-inhibitor-treated cells was reduced by half, whereas SB203580 had no effect. NXT1 was not detected clearly in our experiments for an unknown reason.
There have known at least three posttranscriptional induction mechanisms responsible for the TNFa production by LPS stimulation. 12) Here, we have demonstrated that the Tpl2-MEK-ERK signaling pathway increases the TNFa production through increasing not only nucleocytoplasmic transport of TNFa but also the nuclear TAP without changing its total mRNA level. From the recent proteomics methodology for surveying ERK kinase-phosphorylated substrates, some nucleoporin proteins have been highlighted. 20) For example, nuclear migration of importin-b and transportin was impaired in ERK-activated, digitonin-permeabilized cells, as a result of ERK phosphorylation of Nup50. Matzat et al. reproted that formation of a TAP homotypic complex mediated through the N-terminal portion of TAP stimulates an interaction with nucloporins. This mechanism is independent of RNA binding to the TAP homotypic complex. 21) It is clear that ERK kinase-directed target proteins are largely involved in the nucleocytoplasmic transport systems. There remain many issues to be resolved about the detailed mechanisms of TAP regulation. The Tpl2-MEK-ERK signaling pathway also regulates the processing of pre-TNFa in LPS-stimulated macrophages. 22) Therefore, Tpl2 might be involved in multiple steps of TNFa production at not only the post-transcriptional but also the translational stages. Our results improve understanding of TNFa regulatory mechanisms and might provide a new therapeutic strategy against inflammatory diseases.
